The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting-Reference-Cited by-同舟云学术

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting

Published:2018-06 Issue:6 Volume:8 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer Journal

Author:

De Stefano Valerio,Rocca Bianca,Tosetto Alberto,Soldati Denise,Petrucci Giovanna,Beggiato Eloise,Bertozzi Irene,Betti Silvia,Carli Giuseppe,Carpenedo Monica,Cattaneo Daniele,Cavalca Viviana,Dragani Alfredo,Elli Elena,Finazzi Guido,Iurlo Alessandra,Lanzarone Giuseppe,Lissandrini Laura,Palandri Francesca,Paoli Chiara,Rambaldi Alessandro,Ranalli Paola,Randi Maria Luigia,Ricco Alessandra,Rossi Elena,Ruggeri Marco,Specchia Giorgina,Timillero Andrea,Turnu Linda,Vianelli Nicola,Vannucchi Alessandro M.,Rodeghiero Francesco,Patrono Carlo

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-018-0078-3.pdf

Reference48 articles.

1. Tefferi, A., Vannucchi, A. M. & Barbui, T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 8, 2 (2018).

2. Ryden, L. et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD-summary. Diab. Vasc. Dis. Res. 11, 133–173 (2013).

3. De Stefano, V. et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93, 372–380 (2008).

4. Vardiman, J. W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937–951 (2009).

5. Deadmond, M. A. & Smith-Gagen, J. A. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. J. Cancer Res. Clin. Oncol. 141, 2131–2138 (2015).

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial;American Journal of Hematology;2024-06-15

2. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management;American Journal of Hematology;2024-01-25

3. Thrombotic Prediction Model Based on Epigenetic Regulator Mutations in Essential Thrombocythemia Patients Using Survival Analysis in Recurrent Events;Clinical and Applied Thrombosis/Hemostasis;2024-01

4. BCR::ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera;Physiology International;2023-09-05

5. Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2023-06-26